LRP6 and metabolic syndrome: Certain mutations on the Wnt ligand coreceptor lipoprotein receptor-related protein 6 (LRP6) are associated with the susceptibility of dyslipidemia [30], whereas in mice, Lrp6-deficiency–induced hyperlipidemia can be partially reversed by Wnt-3a administration [31].